Andreas Emmenegger
Direktor/Vorstandsmitglied bei LUZERNER KANTONALBANK AG
Profil
Andreas Emmenegger is the founder of PIQUR Therapeutics AG, which was founded in 2011.
He held the position of Member-Supervisory Board from 2011 to 2018.
Mr. Emmenegger is also the founder of Targimmune Therapeutics AG.
Currently, Mr. Emmenegger holds multiple positions.
He is a Member-Supervisory Board at Luzerner Kantonalbank AG since 2016.
He is also a Member-Management Board at Molecular Partners, Inc. and the Chief Financial Officer at Owkin Switzerland SARL.
Mr. Emmenegger has held several former positions.
From 2006 to 2007, he was the Head-Strategic Alliance Finance at F.
Hoffmann-La Roche Ltd.
He served as the Chief Financial Officer at Interroll Holding AG from 1997 to 2000 and at The Fantastic Co. AG from 2000 to 2003.
From 2005 to 2006, he held the position of Chief Financial Officer at Roche Glycart AG.
He was the Chief Financial Officer at Molecular Partners AG from 2006 to 2022.
Additionally, he worked as a Principal at Roche & Genentech, Inc. He started his career as a Controller at Dräger Beteiligungen AG from 1992 to 1996.
Mr. Emmenegger's education includes an undergraduate degree from Lucerne University of Applied Sciences & Arts.
He also holds undergraduate and MBA degrees from Instituto de Estudios Superiores de la Empresa.
Aktive Positionen von Andreas Emmenegger
| Unternehmen | Position | Beginn |
|---|---|---|
| LUZERNER KANTONALBANK AG | Direktor/Vorstandsmitglied | 01.01.2016 |
Targimmune Therapeutics AG
 Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | Gründer | - |
Molecular Partners, Inc.
 Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Andreas Emmenegger
| Unternehmen | Position | Ende |
|---|---|---|
| MOLECULAR PARTNERS AG | Finanzdirektor/CFO | 31.12.2022 |
PIQUR Therapeutics AG
 PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Gründer | 01.04.2018 |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01.01.2007 |
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Finanzdirektor/CFO | 01.01.2006 |
| THE FANTASTIC COMPANY AG | Finanzdirektor/CFO | 01.01.2003 |
Ausbildung von Andreas Emmenegger
| Instituto de Estudios Superiores de la Empresa | Masters Business Admin |
| Lucerne University of Applied Sciences & Arts | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| MOLECULAR PARTNERS AG | Health Technology |
| LUZERNER KANTONALBANK AG | Finance |
| INTERROLL HOLDING AG | Producer Manufacturing |
| Private Unternehmen | 8 |
|---|---|
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Health Technology |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
| Roche & Genentech, Inc. | |
PIQUR Therapeutics AG
PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Health Technology |
The Fantastic Co. AG
 The Fantastic Co. AG Financial ConglomeratesFinance The Fantastic Co. AG operates as a holding company. It engages in purchasing, retaining and administering shareholdings in other companies. The firm offers accessories and fashion products through their retail partners. The company was founded on November 15, 1996 and is headquartered in Zug, Switzerland. | Finance |
| Dräger Beteiligungen AG | |
Targimmune Therapeutics AG
Targimmune Therapeutics AG Pharmaceuticals: MajorHealth Technology Targimmune Therapeutics AG engages in the drug development using novel targeted onco-immunotherapies. The company was founded by Andreas Emmenegger and Peter Kash and is headquartered in Basel, Switzerland. | Health Technology |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | Health Technology |
